Sickle Cell Disease is a genetic blood disorder that affects hemoglobin, causing red blood cells to become rigid and ...

The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or ...

CD163 is a macrophage receptor that clears hemoglobin-haptoglobin complexes from blood, preventing oxidative damage and also ...

TOKYO, Japan & MUNICH, Germany I April 08, 2025 I DATROWAY® (datopotamab deruxtecan) has been approved in the European Union (EU) for the treatment of ...

Pope Francis was hospitalized on Feb. 14 after suffering a bout of bronchitis for weeks and after increasingly finding it hard to speak publicly.

Modus Therapeutics Holding AB (“Modus”) today announces that the company has secured access to bridge financing of up to SEK 5.0 million from its largest shareholder, Karolinska Development AB. The ...

A new report by the United Nations Maternal Mortality Estimation Inter-Agency Group reveals that Pakistan is among four countries—alongside Nigeria, ...

AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...

Serious adverse reactions in >2% of patients included sepsis (4.2%) and fracture (3.4 ... with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Minimal residual disease negativity was achieved at a significantly higher rate with venetoclax-based therapies, supporting its role in CLL.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval ...